Pascal Janne
Université catholique de Louvain
Publications 804
#1Deepa Rangachari (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 11
#2Ciric To (Harvard University)H-Index: 1
Last.Pascal Janne (Harvard University)H-Index: 110
view all 0 authors...
Abstract Introduction Osimertinib is approved for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), and identification of on-target mechanisms of resistance (i.e. EGFR-C797S) to this 3rd generation EGFR inhibitor are evolving. Whether durable control of subsequently osimertinib-resistant NSCLC with EGFR-sensitizing mutation (SM)/C797S is possible with 1st generation EGFR inhibitors (such as gefitinib or erlotinib) remains underreported, as does the resu...
#1Thomas E. Stinchcombe (Durham University)H-Index: 29
#2Pascal Janne (Harvard University)H-Index: 110
Last.Anthony J. Jaslowski (Saint Vincent Hospital)H-Index: 9
view all 0 authors...
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. Objective To determine whether adding bevacizumab to erlotinib treatment results in superior progression-free survival compared with erlotinib alone. Design, Setting, and Participants This phase 2 randomized clinical trial compared erlotinib plus bevacizumab with...